Transcriptomic analysis of pulmonary artery smooth muscle cells identifies new potential therapeutic targets for idiopathic pulmonary arterial hypertension
Abstract
Pulmonary arterial hypertension (PAH, type 1 pulmonary hypertension) has a 3‐year survival of ~50% and is in need of new, effective therapies. In PAH, remodelling of the pulmonary artery (PA) increases pulmonary vascular resistance and can result in right heart dysfunction and failure. Genetic mutations can cause PAH but it can also be idiopathic (IPAH). Enhanced contractility and proliferation of PA smooth muscle cells (PASMCs) are key contributors to the pathophysiology of PAH, but the underlying mechanisms are not well understood.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 15, 2020
- Source ID
- 10.1111/bph.15074
Entities
People
- Abinaya Muthusamy
- Krishna Sriram
- Matthew W Gorr
- Paul A. Insel
Organizations
- National Heart, Lung, and Blood Institute
- Ohio State University
- United States Department of Defense
- University of California
- University of California, San Diego